Inventor · disambiguated record
Patrick Baeuerle
Also filed as: BAEEUERLE PATRICK · BAEUERLE PATRICK · BAEUERLE PATRICK A · BAEUERLE PATRICK ALEXANDER
44 granted patents·31 pending applications·1,027 citations·filing 1994–2025
98Inventor score
Files withTCR2 THERAPEUTICS INC21HARPOON THERAPEUTICS INC10WEREWOLF THERAPEUTICS INC8AMGEN INC7MICROMET AG5
Top patents by PatentIndex Score
75 records- 0198US9708412B2Trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2016·Granted Jul 18, 2017·66 cites·12 claims
- 0297US11028142B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Granted Jun 8, 2021·6 cites·30 claims
- 0397US7235641B2Bispecific antibodiesMICROMET AG·Filed 2003·Granted Jun 26, 2007·167 cites·2 claims
- 0496US11352403B2Activatable interleukin-2 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Granted Jun 7, 2022·6 cites·13 claims
- 0596US10696724B2Activatable interleukin-2 polypeptidesWEREWOLF THERAPEUTICS INC·Filed 2019·Granted Jun 30, 2020·18 cites·11 claims
- 0696US10442849B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2017·Granted Oct 15, 2019·21 cites·27 claims
- 0796US10208285B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Feb 19, 2019·14 cites·20 claims
- 0896US8007796B2Means and methods for the treatment of tumorous diseasesMICROMET AG·Filed 2006·Granted Aug 30, 2011·69 cites·18 claims
- 0995US11085021B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2020·Granted Aug 10, 2021·3 cites·27 claims
- 1095US10849973B2Prostate specific membrane antigen binding proteinHARPOON THERAPEUTICS INC·Filed 2017·Granted Dec 1, 2020·10 cites·8 claims
- 1195US10844134B2PSMA targeting trispecific proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2017·Granted Nov 24, 2020·12 cites·11 claims
- 1295US10696723B2Activatable interleukin 12 polypeptidesWEREWOLF THERAPEUTICS INC·Filed 2019·Granted Jun 30, 2020·15 cites·12 claims
- 1394US11535658B2Activatable interleukin-2 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2021·Granted Dec 27, 2022·2 cites·21 claims
- 1493US11981716B2Activatable interleukin-2 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2021·Granted May 14, 2024·2 cites·13 claims
- 1593US10358474B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Jul 23, 2019·9 cites·30 claims
- 1692US12128102B2Constrained conditionally activated binding proteinsTAKEDA PHARMACEUTICALS CO·Filed 2023·Granted Oct 29, 2024·1 cites·15 claims
- 1792US11242376B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2017·Granted Feb 8, 2022·6 cites·19 claims
- 1892US10954311B2Trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2017·Granted Mar 23, 2021·9 cites·21 claims
- 1992US7919089B2Pharmaceutical composition comprising a bispecific antibody for EpCAMMICROMET AG·Filed 2004·Granted Apr 5, 2011·57 cites·3 claims
- 2091US8840888B2Dosage regimen for administering a CD19XCD3 bispecific antibodyNAGORSEN DIRK·Filed 2010·Granted Sep 23, 2014·23 cites·34 claims
- 2191US7332168B2Composition for the elimination of autoreactive B-cellsMICROMET AG·Filed 2001·Granted Feb 19, 2008·42 cites·2 claims
- 2291US6410516B1Nuclear factors associated with transcriptional regulationHARVARD COLLEGE·Filed 1995·Granted Jun 25, 2002·167 cites·203 claims
- 2388US10358473B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Jul 23, 2019·4 cites·30 claims
- 2488US7323440B2De-immunized MOG (poly)peptide constructsMICROMET AG·Filed 2003·Granted Jan 29, 2008·41 cites·8 claims
- 2588US2024301026A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2687US6150090ANuclear factors associated with transcriptional regulationMASSACHUSETTS INST TECHNOLOGY·Filed 1995·Granted Nov 21, 2000·69 cites·24 claims
- 2785US2025197526A1Trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2884US11965012B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2022·Granted Apr 23, 2024·0 cites·27 claims
- 2984US11377638B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2018·Granted Jul 5, 2022·1 cites·19 claims
- 3083US5804374ANuclear factors associates with transcriptional regulationMASSACHUSETTS INSTI TECHNOLOGY·Filed 1995·Granted Sep 8, 1998·82 cites·5 claims
- 3182US11753475B2Bispecific-Fc moleculesAMGEN INC·Filed 2018·Granted Sep 12, 2023·1 cites·8 claims
- 3280US11154617B2Means and methods for the treament of B cell non-hodgkin lymphoma and B cell leukemiaBAEUERLE PATRICK·Filed 2011·Granted Oct 26, 2021·4 cites·10 claims
- 3380US6232068B1Monitoring of gene expression by detecting hybridization to nucleic acid arrays using anti-heteronucleic acid antibodiesROSETTA INPHARMATICS INC·Filed 1999·Granted May 15, 2001·69 cites·98 claims
- 3479US11851491B2Compositions and methods for TCR reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2017·Granted Dec 26, 2023·1 cites·15 claims
- 3579US2023212297A1Bispecific fc moleculesAMGEN INC·Filed 2022·Application pending·0 cites
- 3678US12275769B2Activatable interleukin 12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2022·Granted Apr 15, 2025·0 cites·14 claims
- 3777US2022298478A1Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3875US12084518B2Trispecific binding proteins and methods of useHARPOON THERAPEUTICS INC·Filed 2021·Granted Sep 10, 2024·0 cites·21 claims
- 3974US2025179138A1Activatable interleukin 12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4072US10000574B2Compositions comprising polypeptidesHOFMEISTER ROBERT·Filed 2004·Granted Jun 19, 2018·5 cites·15 claims
- 4171US2021206827A9Compositions and methods for tcr reprogramming using fusion proteinsTCR2 THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4270US11453710B2Activatable interleukin 12 polypeptides and methods of use thereofWEREWOLF THERAPEUTICS INC·Filed 2020·Granted Sep 27, 2022·0 cites·16 claims
- 4367US2023212318A1Protease-activatable bispecific proteinsAMGEN INC·Filed 2022·Application pending·0 cites
- 4462US2016145340A1Bispecific-fc moleculesAMGEN INC·Filed 2014·Application pending·0 cites
- 4562US2014302037A1BISPECIFIC-Fc MOLECULESAMGEN INC·Filed 2014·Application pending·0 cites
- 4661US2021100902A1Prostate specific membrane antigen binding proteinHARPOON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4759US2021095047A1PSMA Targeting Trispecific Proteins and Methods of UseHARPOON THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4858US2006063709A1Nuclear factors associated with transcriptional regulationBALTIMORE DAVID·Filed 2002·Application pending·0 cites
- 4957US5891719AIKAP nucleic acidsTULARIK INC·Filed 1997·Granted Apr 6, 1999·10 cites·46 claims
- 5056US2025340651A1Anti-mica/b antibodies with enhanced effector function and methods of useCULLINAN MICA CORP·Filed 2023·Application pending·0 cites
Showing the top 50 of 75 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →